including a low rate of conjunctivitis, which is a recognised side effect with Dupixent. The drug has also been approved in the EU, although it was turned down by the FDA in the US, where rights ...

They also point to lebrikizumab’s safety profile, including low rates of conjunctivitis, which is a known side effect of Dupixent. In trials, Ebglyss showed good and durable efficacy ...